Atomoxetine & Fluoxetine Interaction

Atomoxetine (Strattera) is a selective norepinephrine reuptake inhibitor used for attention deficit hyperactivity disorder (ADHD). Fluoxetine (Prozac) is a selective serotonin reuptake inhibitor (SSRI) used for depression, anxiety, and obsessive-compulsive disorder. These medications are frequently co-prescribed when patients have comorbid ADHD and depression or anxiety.

Fluoxetine is one of the most potent inhibitors of CYP2D6, and atomoxetine is primarily metabolized by this enzyme. The co-administration results in dramatically increased atomoxetine exposure that mimics the pharmacokinetic profile of CYP2D6 poor metabolizers, a phenotype associated with higher rates of adverse effects.

The FDA label for atomoxetine specifically addresses this interaction and recommends dose adjustments when atomoxetine is co-administered with strong CYP2D6 inhibitors like fluoxetine.

Atomoxetine undergoes extensive hepatic metabolism primarily via CYP2D6, with a minor contribution from CYP2C19. The CYP2D6-generated metabolite, 4-hydroxyatomoxetine, has similar pharmacological activity but lower systemic exposure. In CYP2D6 extensive metabolizers, the enzyme accounts for the majority of atomoxetine clearance.

Fluoxetine and its active metabolite norfluoxetine are potent CYP2D6 inhibitors. Norfluoxetine has an exceptionally long half-life (4-16 days), meaning CYP2D6 inhibition persists for weeks after fluoxetine discontinuation. When fluoxetine inhibits CYP2D6, atomoxetine AUC increases approximately 6- to 8-fold, and peak plasma concentrations increase approximately 3- to 4-fold — essentially converting all patients to the CYP2D6 poor metabolizer phenotype.

The clinical significance is high because the magnitude of the pharmacokinetic change is substantial. A 6- to 8-fold increase in atomoxetine exposure places patients at significantly increased risk for dose-dependent adverse effects including elevated heart rate, elevated blood pressure, nausea, decreased appetite, insomnia, and, in rare cases, hepatotoxicity.

Cardiovascular effects are particularly concerning. Atomoxetine causes dose-dependent increases in heart rate (average 5-10 bpm at standard doses) and blood pressure (average 2-4 mmHg systolic). These effects are amplified at the elevated drug concentrations produced by CYP2D6 inhibition and can be clinically significant in patients with pre-existing cardiovascular conditions.

Additionally, both fluoxetine and atomoxetine increase norepinephrine levels (atomoxetine directly, fluoxetine indirectly through serotonin-norepinephrine cross-talk), creating potential for additive sympathomimetic and cardiovascular effects.

When this combination is deemed clinically necessary, the atomoxetine dose should be reduced. The FDA recommends initiating atomoxetine at 0.5 mg/kg/day in children and adolescents, or 40 mg/day in adults, when used with strong CYP2D6 inhibitors. The dose should only be increased to the usual target dose if symptoms do not improve after 4 weeks and the initial dose is well tolerated.

It is important to note that norfluoxetine has a very long half-life (up to 16 days). CYP2D6 inhibition persists for 4-5 weeks after fluoxetine discontinuation. If fluoxetine is stopped, atomoxetine dose adjustments should not be made for at least 5 weeks.

Blood pressure and heart rate should be measured before starting the combination and regularly during treatment. Pre-existing cardiovascular conditions should be evaluated before initiation, and patients should be referred for cardiac evaluation if they develop symptoms such as palpitations, chest pain, or syncope.

Blood pressure and heart rate should be measured at baseline, during dose titration, and periodically during maintenance therapy (at least quarterly). In children and adolescents, growth (height and weight) should be monitored, as atomoxetine can suppress appetite.

Liver function tests should be checked at baseline and if symptoms of hepatotoxicity develop (jaundice, dark urine, right upper quadrant pain, unexplained flu-like symptoms). While rare, atomoxetine-associated hepatotoxicity has been reported, and higher drug levels may increase this risk.

Patients should be monitored for mood changes, particularly increased anxiety, irritability, or suicidal ideation, as both medications carry FDA black box warnings regarding suicidality in children, adolescents, and young adults.

For ADHD in patients on fluoxetine, stimulant medications (methylphenidate, amphetamine salts) do not undergo CYP2D6 metabolism and avoid this specific pharmacokinetic interaction, though they have their own considerations. If an SNRI-type ADHD medication is preferred, the fluoxetine could potentially be switched to an SSRI with less CYP2D6 inhibition (sertraline, citalopram, escitalopram) to reduce the magnitude of the interaction.